New patients assessed at various timepoints - Q3 2022Here is a efficacy snapshot of new patients treated in Q3 at various timepoints:
1) 90 days
- 5 patients assessed, 4 CR (80%), 0 PR (0%), 1 NR (20%)
2) 180 days
- 4 patients assessed, 1 CR (25%), 0 PR (0%), 3 NR (75%)
3) 270 days
- 5 patients assessed, 2 CR (40%), 0 PR (0%), 3 NR (60%),
4) 360 days
- 8 patients assessed, 1 CR (13%), 2 PR (25%), 5 NR (63%)
5) 540 days
- 5 patients assessed, 3 CR (60%), 0 PR (0%), 2 NR (40%)
Observations:
1) CR percentage (80%) at 90 days improved significantly compared to past
2) NR percentage at 180 days increased remarkable (75%)
3) NR at 270 days (60%) just asfter 2nd treatment is remarkably high
4) CR at 360 days (13%) dropped significanly compared to overall CR 29%
5) CR at 540 days (60%) is pretty good compared to overall CR 28%